

Guidelines Breast Version 2024.1E

Diagnosis and Treatment of Patients with early and advanced Breast Cancer

Adjuvant Endocrine-based Therapy in preand postmenopausal Patients

FORSCHEN LEMREN MEILEN



Guidelines Breast Version 2024.1E

Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients

Versions 2002–2023:

Bauerfeind / Dall / Diel / Fasching / Fersis / Fehm / Friedrich / Friedrichs / Gerber / Göring / Hanf/ Harbeck / Huober / Jackisch / Lisboa / Loibl / Lück / Lux / Maass / von Minckwitz / Möbus / Müller / Nitz / Oberhoff / Schaller / Scharl / Schneeweiss / Schütz / Solomeyer / Stickeler / Thomssen / Untch

Version 2024:

Lux / Wöckel

www.ago-online.de



Assessment of Steroid Hormone Receptor Status

AGO: ++

[©] AGO e. V. in der DGGG e.V. sowie in der DKG e.V.

Guidelines Breast Version 2024.1E

Endocrine responsive – hormone receptor positive Immunhistology (ER and/or PgR)

Oxford LoE: 1

0%	pos. cells:	endocrine resistant
1–10%	pos. cells:	possibly endocrine sensitive
> 10%	pos. cells:	endocrine sensitive
Unknow receptor	n hormone status:	endocrine sensitive

GR: A

www.ago-online.de

FORSCHEN LEHREN HEILEN If ER negative / PR positive (> 10% positive cells): reassess IHC status If ER low (1-10%): Implications for therapy should be recommended in the pathology report



© AGO e. V. in der DGGG e.V. sowie in der DKG e.V.

Guidelines Breast Version 2024.1E

Adjuvant Endocrine Therapy Assessment of Menopausal Status

	Oxford			
	LoE	GR	AGO	
Assessment of menopausal status:				•
 Menstruation history 			++	
 FSH, E2 			++	



Adjuvant	End	locri	ine 1	Therapy

[©] AGO e. V. in der DGGG e.V. sowie in der DKG e.V.		Oxf	ord	
Guidelines Breast Version 2024.1E		LoE	GR	AGO
	 Endocrine responsive Endocrine doubtful responsiveness 	1a 3b	A D	++ +
	 Endocrine therapy sequentially after CT 	2a	В	+
	 Endocrine therapy simultaneous to anti-HER2 therapy (w/o chemotherapy) 	2 b	В	+
www.ago-online.de	 Not sensitiv to endocrine therapy 	1a	Α	



Guidelines Breast Version 2024.1E

General Principles in Adjuvant Endocrine Therapy AGO ++

- Adjuvant endocrine therapy is divided into initial therapy (years 1-5), extended adjuvant therapy (EAT, years 6-10+) and adjuvant endocrine-based treatment (years 1-2).
- Standard treatment duration is 5 years.
- Extended therapy and initial adjuvant endocrine-based therapy should be considered based on individual risks and benefits.
- Duration, choice & sequence of AI or Tam or the combination with GnRHa mainly depend on menopausal status, tolerability, and risk of recurrence.
- Switch to another better tolerated endocrine treatment (Tam or AI) or Tam low dose is better than stopping endocrine therapy altogether.
- AI should be used as first treatment in patients, in case of lobular cancers and / or high risk of recurrence.
- FORSCHEN LEHREN HEILEN

www.ago-online.de

 To date, there is no sufficiently validated biomarker for identification of patients at risk for early versus late recurrence.





Guidelines Breast Version 2024.1E

Premenopausal Patients Initial Adjuvant Endocrine Therapy (Year 1-5)

	Oxford		
	LoE	GR	AGO
Low recurrence risk:			
 Tamoxifen for 5 years 	1 a	Α	++
Increased recurrence risk:			
 OFS 2-5 years* + tamoxifen for 5 years 	1 a	Α	++
 OFS[#] + AI for 5 years 	1 a	Α	++
 GnRHa monotherapie (If severe contraindications for Tam exist, compared to no therapy) 	1 a	В	+

OFS: ovarian function suppression;

www.ago-online.de

- * as long as tolerated and the patient is clearly premenopausal after chemotherapy if ovarian function resumes within 24 months. The application of chemotherapy in the trials served as surrogate for high recurrence risk
- # in premopausal women AI only in combination with OFS



[©] AGO e. V. in der DGGG e.V

in der DKG e.V. Guidelines Breas Version 2024.1E

www.ago-online.c

HFII FN

sowie

Adjuvant endocrine therapy in premenopausal patients (OFS + TAM / AI)

	Events/women (%)				Ratio of annual even rates, aromatase inhibitor:tamoxifen
	Allocated aromatase inhibito	Allocated r tamoxifen				
By trial (χ ₃ =8·8; p=0·032)						
ABCSG XII ⁵⁶	114/855 (13.3%)	103/839 (12.3%)				— 1.07 (0.75–1.54)
TEXT ^{7,8}	137/1324 (10.3%)	195/1311 (14.9%)	_			0.64 (0.48-0.85)
SOFT ^{7,8}	115/999 (11.5%)	139/999 (13.9%)			<u> </u>	0.83 (0.60-1.16)
HOBOE ⁹	38/350 (10.9%)	47/353 (13.3%)			<u> </u>	0.72 (0.41-1.27)
A						
	Events/women-years (percentage per year)					Ratio of annual event rates, aromatase inhibitor:tamoxifen (CI)
	Allocated aromatase inhibitor	Allocated Tamoxifen				
Nodal status (trend χ_1^2 =11·1; p=0·0009)						
NO	54/8920 (0-6%)	110/8705 (1.3%)				0-49 (0-32-0-73)
N1-3	63/4292 (1.5%)	112/4315 (2.6%)		-		0.56 (0.38-0.83)
N4+	90/1515 (5.9%)	82/1418 (5.8%)	-	-		1.02 (0.68–1.54)
HER2 status (χ²=3·9; p=0·048)						
HER2 positive	41/1595 (2.6%)	40/1610 (2.5%)				0.93 (0.51–1.68)
HER2 negative	136/10623(1.3%)	235/10356 (2.3%)				0.56 (0.43-0.73)
HER2 unknown	31/2500 (1.2%)	29/2463 (1.2%)		P		1·01 (0·52–1·99)
Total	208/14736 (1·4%)	304/14 445 (2.1%)	\diamond			0.65 (0.55-0.78)
- 99% CI <∞> 95% CI		0	0.5	1.0	1.5	2.0
		Favours aron	natase inhibi	tor Fav	ours tamo	xifen
			Treatmen	t effect p	:0.00001	

EBCTCG: Lancet Oncol. 2022;23:382-392



©AGO e. V. in der DGGG e.V. sowie in der DKG e.V.


Guidelines Breast Version 2024 1F



www.ago-online.de

RSCHEN HDFN MEILEN

Adjuvant endocrine therapy in premenopausal patients (OFS + TAM / AI)



Distant recurrence

All-case mortality

EBCTCG: Lancet Oncol. 2022;23:382-392



Postmenopausal Patients Initial Adjuvant Endocrine Therapy (Years 1-5)

[©] AGO e. V. in der DGGG e.V.		Oxford		
sowie in der DKG e.V.		LoE	GR	AGO
Guidelines Breast Version 2024.1E	 Aromatase inhibitor (AI) for first 5 years 	1 a	Α	++
	 Non steroidal-AI in lobular cancer 	2b	В	+
	 High risk of recurrence 	2b	В	+
	Sequential therapy for first 5 years *	1a	Α	++
	 Tam (2-3 yrs.) followed by AI to complete 5 years 	1 a	Α	++
	 AI (2-3 yrs.) followed by tamoxifen to complete 5 years 	1b	С	++
	Tamoxifen 20 mg/d for 5 years**	1 a	Α	+


www.ago-online.de

- SCHEN * in postmenopausal patients, AI should be integrated in the first five years
 - ** Tamoxifen may be offered to individual patients with very low risk of recurrence or if contraindications for AI are present



Guidelines Breast Version 2024.1E

Aromatase Inhibitor vs. Tamoxifen vs. Sequential Therapy - 5 years up-front Therapy



www.ago-online.de

FORSCHEN LEHREN HEILEN

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2015 Oct 3;386(10001):1341-52.



Guidelines Breast Version 2024.1E

Adjuvante Endocrine-Based Therapy with CDK4/6 Inhibitors and PARP Inhibitors

V. GG e.V.		Oxford			
Ge.V.		LoE	GR	AGO	
Breast 024.1E	In patients with increased risk of recurrence, characteristics and drug doses corresponding to study criteria				
	Abemaciclib for 2 years*	1b	В	+	
	 Olaparib for 1 year in patients with gBRCA1/2 mutations** 	1b	В	++	


www.ago-online.de

- FORSCHEN LEHREN HEILEN
- * corresponding to MonarchE-Study
- ** corresponding to OlympiA-Study




©AGO e. V. in der DGGG e.V. sowie in der DKG e.V.

Guidelines Breast Version 2024.1E



FORSCHEN I FHDFN HEII EN

How to calculate CPS+EG Score?



Mittendorf EA, J Clin Oncol 2011;29:1956-1962 Marmé F, et al. Eur J Cancer 2021;153:203-212

Nuclear grade 3

Clinical Stage

IIA 0

IIB 1

IIIA 1

IIIB 2

0

IIA

IIB 1

IIIA 1

IIIB 1

ER negative

0

0

0

1



Adjuvant / Post-Neoadjuvant Treatment with CDK4/6i

·.		monarchE	PALLAS	PENELOPE ^B	NATALEE
Ge.V.	N	5,637	5,600	1,250	5,101
e.V. Breast	CDK4/6i	Abemaciclib	Palbociclib	Palbociclib	Ribociclib
4.1E	% of pts. with NACT	37%	n.r.	100%	n.a.
	Duration of CDK4/6i treatment	24 months	24 months	12 months	36 months
	Follow-up	42.0 months	24 months	43 months	33.3 months
	Discontinuation rate	30.6%	42%	20%	35.5%
	Discontinuation rate due to AE _{CDKi}	18.5%	27%	5%	19.5%
	IDFS-HR (95%-CI)	0.664 (0.578-0.762) p < 0.0001	0.96 (0.81-1.14) p = 0.65	0.93 (0.74-1.16) p = 0.525	0.749(0,628-0.892) P=0.0006
	2-yrs IDFS	92.7% vs. 89.9%	n.r.	88% vs. 78%	93.5% vs. 92.0%
-online.de	3-yrs IDFS	89.2% vs. 84.4%	88% vs. 89%	81% vs. 78%	90.7% vs. 87.6%
	4-yrs IDFS	85.8% vs. 79.4%	84.2% vs. 84.5%	73% vs. 72%	

IDFS: invasive disease-free survival





[©] AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast Version 2024.1E

Premenopausal Patients Extended Adjuvant Endocrine Therapy (EAT) (Years 6–10)

	Oxf		
	LoE	GR	AGO
In case of high risk of recurrence			
 5 years tamoxifen after 5 years tamoxifen 	1 a	Α	++
 2,5 – 5 years AI after 5 years tamoxifen in initially premenopausal patients who obtain validated postmenopausal status during course of therapy 	1b	В	+
5 years tamoxifen after 5 years of endocrine therapy + OFS	5	D	+

www.ago-online.de





[®] AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast Version 2024.1E

	Oxioid			
	LoE	GR	AGO	
In case of high risk of recurrence				
5 years tamoxifen after 5 years tamoxifen	1 a	Α	+	
 2–5 years AI after 5 years tamoxifen 	1 a	Α	++	
 After initial AI-containing therapy (upfront or switch), prolongation of endocrine therapy with AI in total for 7-8 years* 				
 High-risk of recurrence and good tolerability of AI, good bone health 	1a	Α	+	
 Low-risk, poor tolerability of Al 	1 a	Α	-	
 Interruption of endocrine treatment up to 3 months during EAT with AI 	1b	В	+/-	

Postmenopausal Patients

Extended Adjuvant Endocrine Therapy (EAT) (Years 6–10)


Ovford

* Up to date, no impact on OS

www.ago-online.de




Guidelines Breast Version 2024.1E



FORSCHEN LEHREN HEILEN

Extended Aromatase Inhibitor Treatment following 5 or more Years of Endocrine Therapy: A Metaanalysis of 22192 Women in 11 Randomised Trials (EBCTCG)

Absolute risk reduction (in %) of extended AI therapy differs after 10 years by type of prior endocrine therapy



¹ (new primary breast cancer, local and distant recurrence)

Gray R et al. SABCS 2018 (GS3-03)



Guidelines Breast Version 2024.1E

Decision Criteria for Extended Adjuvant Therapy

Factors indicating a clinical benefit from EAT:

- Adjuvant tamoxifen therapy only
- Condition after chemotherapy (indicating high risk)
- Positive lymph node status and / or T2 / T3 tumors
- Elevated risk of recurrence based on immunohistochemical criteria or based on multi-gene expression assays
- High CTS5-score
- BCI (H/I) (Breast Cancer Index)

Further decision criteria:

- Wish of patient
- up to now well tolerated AI therapy,
- good bone health
- younger age
- adherence

www.ago-online.de

FORSCHE LEMREN MEILEN



Guidelines Breast Version 2024.1E

www.ago-online.de

SCHEN

Ovarian Protection with GnRHa and Fertility Preservation in Premenopausal Patients Receiving (Neo)-Adjuvant Chemotherapy (CT)

	Oxford		
	LoE	GR	AGO
 CTx + GnRHa (preservation of ovarian function) (GnRHa application > 2 weeks prior to chemo- therapy, independent of hormone receptor status) 	1 a	A	+
 CTx + GnRHa (preservation of fertility) 	2 a	В	+/-
 Fertility preservation counselling including referral of all potential patients to appropriate reproductive specialists (ART; further information <u>https://fertiprotekt.com/english</u>; S2k guideline Fertility protection in patients with malignancies) 			++



Fertility Preservation and Assisted Reproductive Therapy (ART) - Oncologic safety¹ -

[©] AGO e. V. in der DGGG e.V.		Oxford						
sowie in der DKG e.V.		LoE	GR	AGO				
Guidelines Breast Version 2024.1E	 Pretreatment approaches to preserve fertility 							
	GnRHa	1 a	Α	++				
	Cryopreservation of ovarian tissue with subsequent transplantation ²	4	D	+				
	Cryopreservation of oocytes (unfertilized / fertilized) after ovarian stimulation	2 a	С	+				
www.ago-online.de	 ART after breast diagnosis of breast cancer 	4	С	+/-				
FORSCHEN LEHREN HEILEN	 ¹Evidence is limited due to studies with poor quality e.g. (prospective randomized trials are not feasible) ² Risk of relapse caused by transplantation of ovarian tissue containing tumor cells from the original malign ovarian tissue is necessary in patients with BRCA1/2 mutations due to increased risk of ovarian cancer 	ancy; remova	I of transpla	anted				




Guidelines Breast Version 2024.1E

Adjuvant endocrine therapy in premenopausal patients with the desire to get pregnant

Temporary interruption of adjuvant endocrine treatment (ET) after 18-30 month of ET, allowing a wash out period of 3 months, the attempt to get pregnant in a period of up to 2 years for those women with the desire to get pregnant does not impact short-term breast cancer outcome.

AGO +


www.ago-online.de



- FORSCHEN LEHREN HEILEN
- If no pregnancy by 1 y., fertility assessment recommended
- ET resumption strongly recommended after pregnancy to complete planned 5-10 yrs.



Guidelines Breast Version 2024.1E




FORSCHER LEHREN HEILEN

Adjuvant endocrine therapy in premenopausal patients with the desire to get pregnant

<u>Pregnancies outcome</u>: 317 (64% of all women) had at least one live birth, 62% reported breast feeding, 2% showed birth defects


BREAST CANCER OUTCOMES – POSITIVE & SOFT/TEXT



12



Guidelines Breast Version 2024.1E



FORSCHEN LEHIREN HEILEN

Adjuvant endocrine therapy in premenopausal patients with the desire to get pregnant

3- YEAR BCFI CUMULATIVE INCIDENCE – POSITIVE only

• 3-year BCFI varied according to clinical-pathological characteristics

Subgroup	No. Events / Total No. Patients		3-Year BCF	l Cumula	tive Inci	dence P	ercent (S	95% CI)
Overall	44/516		-	L				8.9 (6.7-11.9)
Age at enrollment (years)								
<35	14/177	,	-					9.1 (5.4-14.9)
35-39	18/221	-	-	-				7.7 (4.8-12.3)
40-42	12/118			and the second				11.2 (6.5-18.9)
BMI at enrollment (kg/m ²)*								
<25	34/371		-	-				9.5 (6.8-13.2
25 to <30	7/90		-					8.0 (3.9-16.1)
≥30	3/49		•					7.2 (2.4-20.9)
BRCA status								
BRCA Positive	5/38			•			+	14.5 (6.3-31.6
Other mutation	4/21		-					10.5 (2.7-35.9)
No documented mutation	n† 35/457		H					8.4 (6.1-11.5
HER2 status								
Positive	6/134							4.9 (2.2-10.6
Negative	38/382			-				10.4 (7.6-14.1
Nodal status								
pNO	21/342	-						6.6 (4.3-10.0
pN+ 1-3	18/151		-					12.6 (8.1-19.3)
pN+ 4–9	5/23		H		•			18.7 (7.4-42.6
				-	1	1	_	
		0 5	5 10	15	20	25	30	
				Percent				

Subgroup	No. Events / Total No. Patients		3-Y	ear BCF	l Cumulati	ve Incide	nce Perc	ent (95	i% CI)
Tumor size (cm)‡									
≤2	24/331								7.6 (5.1-11.2)
>2 to ≤5	16/161		F	-					10.3 (6.3–16.5)
>5	4/21			-					21.1 (8.3-47.6)
Tumor grade‡									
1 (BRE 3-5)	5/89			-					6.4 (2.7-14.8)
2 (BRE 6-7)	21/252								8.9 (5.8-13.6)
3 (BRE 8-9)	18/172		-	-					10.4 (6.6-16.2)
Breast surgery									
Mastectomy	29/233			-	-	-			12.7 (8.9-17.9)
Breast conservation	15/283		-						5.7 (3.4-9.5)
Prior endocrine therapy									
SERM alone	20/215		F	-					9.9 (6.4-15.1)
SERM+OFS	20/184		1	-					11.4 (7.4–17.4)
AI+OFS	1/82			-					1.2 (0.2-8.4)
Other	3/35			-					8.8 (2.9-24.9)
Prior chemotherapy									
Anthracycline (A) based	8/36					-			19.4 (9.8-36.5)
Taxane (T) based	4/66		• •						6.7 (2.5-16.9)
Both A and T based	16/215								8.4 (5.2-13.4)
Neither A or T based	0/3								
None	16/196			-					8.4 (5.1–13.6)
			-		1	1		_	
		0	5	10	15	20	25	30	
					Percent				



Guidelines Breast Version 2024.1E

www.ago-online.de

FORSCHEN LEHREN HEILEN


Adjuvant endocrine therapy in premenopausal patients with the desire to get pregnant

Ovarian stimulation and breast cancer outcome – results from the POSITIVE trial

1) As part of embryo/oocyte cryopreservation - after BC diagnosis


At 3-years, BCFI-events cumulative incidence

- 9.7% (95% CI: 6.0% to 15.4%) for the 179 patients who underwent ovarian stimulation
- 8.7% (95% CI: 6.0% to 12.5%) for the 318 patients who did not





Guidelines Breast Version 2024.1E



FORSCHEN LEHREN HEILEN

Adjuvant endocrine therapy in premenopausal patients with the desire to get pregnant

Ovarian stimulation and breast cancer outcome – results from the POSITIVE trial

2) As part of ART - after enrollment

- 397 patients alive and BC free at 24-months (landmark analysis)
 - 2 BC events amongst 71 patients in the ovarian stimulation group
 - 8 BC events amongst 326 patients in the non-ovarian stimulation group

